Fibrocell Science Chairman & CEO David Pernock Joins Board of Alliance for Regenerative Medicine

Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, today announced Chairman and CEO David Pernock has joined the board of the Alliance for Regenerative Medicine (ARM), a global advocacy organization whose diverse membership represents leading regenerative medicine companies and investors, university-based and non-profit research institutions, patient advocacy groups, pharmaceutical companies engaged in regenerative medicine research, and other organizations supporting regenerative medicine.

We are honored to be part of this prestigious organization and join with other leaders from science and industry to advance innovative, regenerative medicine technologies, said Mr. Pernock. Fibrocells pursuit of breakthrough, autologous fibroblast cell-based therapies for patients suffering from difficult-to-treat skin diseases exemplifies our focus and commitment to the potential of regenerative medicine. This work is part of our Exclusive Channel Collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, to develop treatments using genetically-modified fibroblasts for orphan skin diseases, including recessive dystrophic epidermolysis bullosa, morphea and cutaneous eosinophilias, and to explore the localized treatment of moderate-to-severe psoriasis, the most common autoimmune skin disease.

Recently, Mr. Pernock was a presenter at the 3rd Annual Regenerative Medicine Partnering Forum, part of this years Stem Cell Meeting on the Mesa held in La Jolla, California. Organized by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the 2013 Stem Cell Meeting on the Mesa was a three-day conference aimed at bringing together senior members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures.

We are delighted to have Fibrocell as a member of the Alliance and to have David join our Board. They are one of the leading cell therapy companies developing new therapies for skin diseases and bring a deep knowledge of fibroblast technology to our organization. We look forward to working with David and his team, commented Morrie Ruffin, Managing Director of ARM.

About Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 145 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (NYSE MKT:FCSC) is an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs. Based on its proprietary autologous fibroblast technology, Fibrocell is pursuing breakthrough medical applications of azficel-T for restrictive burn scarring and vocal cord scarring. The companys collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, includes using genetically-modified fibroblasts for treating orphan skin diseases for which there are no currently approved products and exploring the localized treatment of the most common autoimmune skin disease, moderate-to-severe psoriasis. Fibrocells collaboration with UCLAfocusing on skin-derived stem cells and more efficient ways to convert skin cells to other cell typesholds potential for future discovery and development of autologous cellular therapeutics. For additional information, visit http://www.fibrocellscience.com.

Forward-Looking Statements

All statements in this press release that are not based on historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Companys control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A Risk Factors in the Companys Annual Report on Form 10-K for the year ended December 31, 2012, as updated in Item 1A. Risk Factors in the Companys Quarterly Reports on Form 10-Q filed since the annual report. The Company operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Companys public filings with the SEC.

Read more:
Fibrocell Science Chairman & CEO David Pernock Joins Board of Alliance for Regenerative Medicine